About Harmony test

• Ariosa Diagnostics, Inc., the creator of the Harmony test, started offering the test in 2012
• Ariosa Diagnostics joined Roche, a healthcare partner with a clinical mindset, in 2014
• The Harmony prenatal test is a Roche offering. It is backed by 120+ years of Roche dedication and service
• The test is supported by Roche’s strong technical support and responsible marketing

• A pioneer in healthcare for >120 years
• The frontrunner in personalized healthcare
• The global leader in cancer treatment for over 50 years
• The leading provider of in vitro diagnostics
• World’s number one biotech company with 17 biopharmaceuticals in the market
• Over 90,000 people working in more than 100 countries

Ariosa Diagnostics, Inc. is a leading molecular diagnostics company committed to innovating together to improve patient care.  Ariosa’s technology can be found in its tests and services and in the tests and services offered by its commercial partners.

This page is intended to serve as notice under 35 U.S.C. § 287(a).

Harmony Prenatal Test®:  U.S. Patent Nos. 8,756,020, 8,712,697, 8,700,338.  Additional patents may be pending in the U.S. and elsewhere.

Director™ Software:  U.S. Patent Nos. 8,756,020, 8,712,697, 8,700,338.  Additional patents may be pending in the U.S. and elsewhere.

• Available in more than 100 countries¹
• Used in more than 2 million pregnancies¹
• Proven by more clinical evidence than any other test in the market²
• More accurate than traditional screening³
• Lower false positive rates than traditional screening³